Pharma 61: Antifungal Therapy - Targeting a Near-Neighbour

This episode explores antifungal agents as the pharmacology of narrow discrimination. Fungi are eukaryotes-biologically closer to us than bacteria-so effective therapy depends on exploiting small but crucial differences in cell membranes, cell walls, and replication machinery. We examine ergosterol synthesis and binding, cell wall β-glucan inhibition, nucleic acid synthesis interference, and emerging resistance to understand why antifungal treatment is often prolonged, toxic, and indication-specific. The clinical thread is proportionality: choosing enough power to clear infection without tipping into host harm.Key takeaways to stabilise understanding:* Eukaryotic challenge: why selective toxicity is harder with fungi.* Membrane targets: azoles, polyenes, and ergosterol disruption.* Cell wall strategy: echinocandins and β-glucan synthesis inhibition.* Resistance and relapse: biofilms, non-albicans species, and adaptive pathways.* Clinical judgement: superficial vs invasive disease, host immunity, and duration. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe